The strategic interaction between firms and formulary committees: Effects on the prices of new drugs

We study the strategic interaction between the pricing decisions of a pharmaceutical firm and the reimbursement decisions of a government agency which grants reimbursement rights to patients for whom new drugs are most cost-effective. If the reimbursement decision precedes pricing, the agency only r...

Full description

Saved in:
Bibliographic Details
Published in:Journal of health economics 2008-03, Vol.27 (2), p.377-404
Main Authors: García-Alonso, María D.C., García-Mariñoso, Begoña
Format: Article
Language:English
Subjects:
Businesses
Cost effectiveness
Cost-Benefit Analysis
Decision making
Decision Making, Organizational
Drug formularies
Drug Industry
Drugs
Drugs, Investigational - economics
Government-business relations
Health administration
Health care
Humans
Impact analysis
Models, Econometric
Pharmaceutical industry
Pharmacy and Therapeutics Committee
Price formation
Prices
Pricing
Pricing policies
Public health
Reimbursement
Reimbursement Mechanisms
Strategic behaviour
Studies
Subsidies
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c663t-2d9aad644cf61594759944a9b260226be55e5a0a48f7b1afeae3ae79397d60ce3
cites cdi_FETCH-LOGICAL-c663t-2d9aad644cf61594759944a9b260226be55e5a0a48f7b1afeae3ae79397d60ce3
container_end_page 404
container_issue 2
container_start_page 377
container_title Journal of health economics
container_volume 27
creator García-Alonso, María D.C.
García-Mariñoso, Begoña
description We study the strategic interaction between the pricing decisions of a pharmaceutical firm and the reimbursement decisions of a government agency which grants reimbursement rights to patients for whom new drugs are most cost-effective. If the reimbursement decision precedes pricing, the agency only reimburses some patients if the drug’s private and public health benefits diverge. This is, there are consumption externalities and the variable cost of the drug exceeds the alternative’s. Contrarily, if the firm can commit to a price before reimbursement, a strategic effect implies that by setting a sufficiently high price, the firm can make the agency more willing to reimburse than without commitment.
doi_str_mv 10.1016/j.jhealeco.2007.06.003
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70415944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167629607001129</els_id><sourcerecordid>20849990</sourcerecordid><originalsourceid>FETCH-LOGICAL-c663t-2d9aad644cf61594759944a9b260226be55e5a0a48f7b1afeae3ae79397d60ce3</originalsourceid><addsrcrecordid>eNqFkk1r3DAQhk1pabZp_0IQPfS27ujDktVTS0i_CPSSnoUsj7Na1vZWkhPy7zvLblvoZQWjGcHzDsO8qqorDjUHrt9v6-0G_Q7DXAsAU4OuAeSzasVbY9dcK_28WhFo1lpYfVG9ynkLdBppX1YXvBVGg9Crqr_bIMsl-YL3MbA4FUw-lDhPrMPyiDixIaYxMz_1bJjTuOx8emJhHsdYCmL-wG6GAUPJjCSFmu1TDEivgU34yPq03OfX1YvB7zK-OeXL6ufnm7vrr-vbH1--XX-6XQetZVmL3nrfa6XCoHljlWmsVcrbTtCsQnfYNNh48KodTMf9gB6lR2OlNb2GgPKyenfsu0_zrwVzcWPMAXc7P-G8ZGdAHfqqs2BjRAtctmdBqVtuhTRnQQGtstYCgW__A7fzkiZaCzFNC8KahiB9hEKac044ONrqSIt3HNzBf7d1f_x3B_8daEf-k_D7UZhwj-GvChEJD_PkHpz0wtD1dCgAWkrxUFLsKaQxToFymzJSs6vTqEs3Yv9vhtPvIeDjEUAy9SFicjlEnAL2MdGXcP0czw38G6bU3Wk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>205802975</pqid></control><display><type>article</type><title>The strategic interaction between firms and formulary committees: Effects on the prices of new drugs</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>International Bibliography of the Social Sciences (IBSS)</source><source>Elsevier</source><creator>García-Alonso, María D.C. ; García-Mariñoso, Begoña</creator><creatorcontrib>García-Alonso, María D.C. ; García-Mariñoso, Begoña</creatorcontrib><description>We study the strategic interaction between the pricing decisions of a pharmaceutical firm and the reimbursement decisions of a government agency which grants reimbursement rights to patients for whom new drugs are most cost-effective. If the reimbursement decision precedes pricing, the agency only reimburses some patients if the drug’s private and public health benefits diverge. This is, there are consumption externalities and the variable cost of the drug exceeds the alternative’s. Contrarily, if the firm can commit to a price before reimbursement, a strategic effect implies that by setting a sufficiently high price, the firm can make the agency more willing to reimburse than without commitment.</description><identifier>ISSN: 0167-6296</identifier><identifier>EISSN: 1879-1646</identifier><identifier>DOI: 10.1016/j.jhealeco.2007.06.003</identifier><identifier>PMID: 18276026</identifier><identifier>CODEN: jhecd9</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Businesses ; Cost effectiveness ; Cost-Benefit Analysis ; Decision making ; Decision Making, Organizational ; Drug formularies ; Drug Industry ; Drugs ; Drugs, Investigational - economics ; Government-business relations ; Health administration ; Health care ; Humans ; Impact analysis ; Models, Econometric ; Pharmaceutical industry ; Pharmacy and Therapeutics Committee ; Price formation ; Prices ; Pricing ; Pricing policies ; Public health ; Reimbursement ; Reimbursement Mechanisms ; Strategic behaviour ; Studies ; Subsidies ; United States</subject><ispartof>Journal of health economics, 2008-03, Vol.27 (2), p.377-404</ispartof><rights>2007 Elsevier B.V.</rights><rights>Copyright Elsevier Sequoia S.A. Mar 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c663t-2d9aad644cf61594759944a9b260226be55e5a0a48f7b1afeae3ae79397d60ce3</citedby><cites>FETCH-LOGICAL-c663t-2d9aad644cf61594759944a9b260226be55e5a0a48f7b1afeae3ae79397d60ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904,30978,30979,33202,33203</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18276026$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/eeejhecon/v_3a27_3ay_3a2008_3ai_3a2_3ap_3a377-404.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>García-Alonso, María D.C.</creatorcontrib><creatorcontrib>García-Mariñoso, Begoña</creatorcontrib><title>The strategic interaction between firms and formulary committees: Effects on the prices of new drugs</title><title>Journal of health economics</title><addtitle>J Health Econ</addtitle><description>We study the strategic interaction between the pricing decisions of a pharmaceutical firm and the reimbursement decisions of a government agency which grants reimbursement rights to patients for whom new drugs are most cost-effective. If the reimbursement decision precedes pricing, the agency only reimburses some patients if the drug’s private and public health benefits diverge. This is, there are consumption externalities and the variable cost of the drug exceeds the alternative’s. Contrarily, if the firm can commit to a price before reimbursement, a strategic effect implies that by setting a sufficiently high price, the firm can make the agency more willing to reimburse than without commitment.</description><subject>Businesses</subject><subject>Cost effectiveness</subject><subject>Cost-Benefit Analysis</subject><subject>Decision making</subject><subject>Decision Making, Organizational</subject><subject>Drug formularies</subject><subject>Drug Industry</subject><subject>Drugs</subject><subject>Drugs, Investigational - economics</subject><subject>Government-business relations</subject><subject>Health administration</subject><subject>Health care</subject><subject>Humans</subject><subject>Impact analysis</subject><subject>Models, Econometric</subject><subject>Pharmaceutical industry</subject><subject>Pharmacy and Therapeutics Committee</subject><subject>Price formation</subject><subject>Prices</subject><subject>Pricing</subject><subject>Pricing policies</subject><subject>Public health</subject><subject>Reimbursement</subject><subject>Reimbursement Mechanisms</subject><subject>Strategic behaviour</subject><subject>Studies</subject><subject>Subsidies</subject><subject>United States</subject><issn>0167-6296</issn><issn>1879-1646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>8BJ</sourceid><recordid>eNqFkk1r3DAQhk1pabZp_0IQPfS27ujDktVTS0i_CPSSnoUsj7Na1vZWkhPy7zvLblvoZQWjGcHzDsO8qqorDjUHrt9v6-0G_Q7DXAsAU4OuAeSzasVbY9dcK_28WhFo1lpYfVG9ynkLdBppX1YXvBVGg9Crqr_bIMsl-YL3MbA4FUw-lDhPrMPyiDixIaYxMz_1bJjTuOx8emJhHsdYCmL-wG6GAUPJjCSFmu1TDEivgU34yPq03OfX1YvB7zK-OeXL6ufnm7vrr-vbH1--XX-6XQetZVmL3nrfa6XCoHljlWmsVcrbTtCsQnfYNNh48KodTMf9gB6lR2OlNb2GgPKyenfsu0_zrwVzcWPMAXc7P-G8ZGdAHfqqs2BjRAtctmdBqVtuhTRnQQGtstYCgW__A7fzkiZaCzFNC8KahiB9hEKac044ONrqSIt3HNzBf7d1f_x3B_8daEf-k_D7UZhwj-GvChEJD_PkHpz0wtD1dCgAWkrxUFLsKaQxToFymzJSs6vTqEs3Yv9vhtPvIeDjEUAy9SFicjlEnAL2MdGXcP0czw38G6bU3Wk</recordid><startdate>20080301</startdate><enddate>20080301</enddate><creator>García-Alonso, María D.C.</creator><creator>García-Mariñoso, Begoña</creator><general>Elsevier B.V</general><general>Elsevier</general><general>Elsevier Sequoia S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7T2</scope><scope>8BJ</scope><scope>C1K</scope><scope>FQK</scope><scope>JBE</scope><scope>K9.</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20080301</creationdate><title>The strategic interaction between firms and formulary committees: Effects on the prices of new drugs</title><author>García-Alonso, María D.C. ; García-Mariñoso, Begoña</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c663t-2d9aad644cf61594759944a9b260226be55e5a0a48f7b1afeae3ae79397d60ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Businesses</topic><topic>Cost effectiveness</topic><topic>Cost-Benefit Analysis</topic><topic>Decision making</topic><topic>Decision Making, Organizational</topic><topic>Drug formularies</topic><topic>Drug Industry</topic><topic>Drugs</topic><topic>Drugs, Investigational - economics</topic><topic>Government-business relations</topic><topic>Health administration</topic><topic>Health care</topic><topic>Humans</topic><topic>Impact analysis</topic><topic>Models, Econometric</topic><topic>Pharmaceutical industry</topic><topic>Pharmacy and Therapeutics Committee</topic><topic>Price formation</topic><topic>Prices</topic><topic>Pricing</topic><topic>Pricing policies</topic><topic>Public health</topic><topic>Reimbursement</topic><topic>Reimbursement Mechanisms</topic><topic>Strategic behaviour</topic><topic>Studies</topic><topic>Subsidies</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Alonso, María D.C.</creatorcontrib><creatorcontrib>García-Mariñoso, Begoña</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of health economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Alonso, María D.C.</au><au>García-Mariñoso, Begoña</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The strategic interaction between firms and formulary committees: Effects on the prices of new drugs</atitle><jtitle>Journal of health economics</jtitle><addtitle>J Health Econ</addtitle><date>2008-03-01</date><risdate>2008</risdate><volume>27</volume><issue>2</issue><spage>377</spage><epage>404</epage><pages>377-404</pages><issn>0167-6296</issn><eissn>1879-1646</eissn><coden>jhecd9</coden><abstract>We study the strategic interaction between the pricing decisions of a pharmaceutical firm and the reimbursement decisions of a government agency which grants reimbursement rights to patients for whom new drugs are most cost-effective. If the reimbursement decision precedes pricing, the agency only reimburses some patients if the drug’s private and public health benefits diverge. This is, there are consumption externalities and the variable cost of the drug exceeds the alternative’s. Contrarily, if the firm can commit to a price before reimbursement, a strategic effect implies that by setting a sufficiently high price, the firm can make the agency more willing to reimburse than without commitment.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>18276026</pmid><doi>10.1016/j.jhealeco.2007.06.003</doi><tpages>28</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0167-6296
ispartof Journal of health economics, 2008-03, Vol.27 (2), p.377-404
issn 0167-6296
1879-1646
language eng
recordid cdi_proquest_miscellaneous_70415944
source Applied Social Sciences Index & Abstracts (ASSIA); International Bibliography of the Social Sciences (IBSS); Elsevier
subjects Businesses
Cost effectiveness
Cost-Benefit Analysis
Decision making
Decision Making, Organizational
Drug formularies
Drug Industry
Drugs
Drugs, Investigational - economics
Government-business relations
Health administration
Health care
Humans
Impact analysis
Models, Econometric
Pharmaceutical industry
Pharmacy and Therapeutics Committee
Price formation
Prices
Pricing
Pricing policies
Public health
Reimbursement
Reimbursement Mechanisms
Strategic behaviour
Studies
Subsidies
United States
title The strategic interaction between firms and formulary committees: Effects on the prices of new drugs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A50%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20strategic%20interaction%20between%20firms%20and%20formulary%20committees:%20Effects%20on%20the%20prices%20of%20new%20drugs&rft.jtitle=Journal%20of%20health%20economics&rft.au=Garc%C3%ADa-Alonso,%20Mar%C3%ADa%20D.C.&rft.date=2008-03-01&rft.volume=27&rft.issue=2&rft.spage=377&rft.epage=404&rft.pages=377-404&rft.issn=0167-6296&rft.eissn=1879-1646&rft.coden=jhecd9&rft_id=info:doi/10.1016/j.jhealeco.2007.06.003&rft_dat=%3Cproquest_cross%3E20849990%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c663t-2d9aad644cf61594759944a9b260226be55e5a0a48f7b1afeae3ae79397d60ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=205802975&rft_id=info:pmid/18276026&rfr_iscdi=true